This site is intended for US healthcare professionals.
Achieving Later-Line Benefits
Research is pursuing effective and tolerable therapy, potentially offering hope for patients with rrRCC15,16
Because treatment decisions take into account safety and tolerability, including the impact of comorbidities and prior therapies,8 the development of well-tolerated treatment options is essential to continuing care
Delaying symptoms is an essential goal: progressing symptomatic disease imposes a significant burden of complications, pain, and physical limitations, negatively impacting quality of life17
As RCC advances, quality of life implications become increasingly important18
Finding effective and tolerable treatment is especially critical in later-line RCC since AEs continue to pose a clinical challenge and poor performance status can be a barrier to receiving therapy13,19
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!